| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2025 | 24 Jan 2025 |
| BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Unaudited standalone and consolidated financial results for the quarter ended 31.12.2024 and to consider fund raising options . Board of Directors at their meeting held on 13.02.2024 has inter alia , 1.Taken on record and approved Unaudited stand alone and consolidated financial results for the quarter and 9 months ended 31.12.2024. 2. Differed to consider fund raising options due to unfavorable and volatile market conditions. Additional details for Corporate Announcement filed under Regulation 30 of SEBI(LODR)Regulations,2015, dated 13.02.2025. (As per BSE Announcement Dated on 13/02/2025) | ||
| Board Meeting | 14 Nov 2024 | 5 Nov 2024 |
| BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30.09.2024 Board of Directors at their meeting held on 14.11.2024 has inter alia taken on record and approved the Un-audited financial results of the Company for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on: 14/11/2024) | ||
| Board Meeting | 9 Sep 2024 | 30 Aug 2024 |
| BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2024 inter alia to consider and approve 1. Allotment of equity shares to the employees of the Company upon conversion of stock options vested on them. 2. To consider expanding its manufacturing presence to meet growing demand for APIs. 3.Any other matters incidental to the business operations and ensuing AGM of the Company. Outcome of the Board Meeting- Announcement under Regulation 30 of SEBI(LODR) Regulations. (As Per BSE Announcement Dated on 09.09.2024) Further to our intimation to the exchanges reg the Outcome of Board meeting dated 09.09.2024, we would like to clarify that the actual cost of the project that is being undertaken at Kadechur KIADB Industrial area, Yadgir Distriact, Karnataka is estimated to be around Rs.40 Crores and not Rs.30 Crores as stated in our above mentioned intimation inadvertently. Request you to please take this intimation on record. Read less.. (As Per BSE Announcement Dated on 11.09.2024) | ||
| Board Meeting | 12 Aug 2024 | 26 Jul 2024 |
| BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve 1. Un-Audited financial Results for the quarter ended 30.06.2024. 2.To review the requests of the promoters for reclassification. 3. To convene 37th Annual General Meeting of the Company. 4. To Decide on Book Closure dates. 5. Other AGM related matters. 6. Allotment of equity shares to the employees of the Company upon conversion of stock options. Inter alia 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2024. 2. Convened 37th Annual General Meeting of the Company on 25th September 2024. 3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2024 to 25.09.2024(both days inclusive ) to ascertain the entitlement of Dividend and for 37th AGM. 4.Approved the re-classification of promoter share holding subject to the approval of shareholders. As per Regulation 31 A (8)(b) of LODR Regulations, we are circulation the extract of the minutes of BOD held on 12.08.2024 pertaining to reclassification of promoters. (As Per BSE Announcement Dated on 03.12.2024) | ||
| Board Meeting | 28 May 2024 | 30 Apr 2024 |
| BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve 1.Audited Standalone and Consolidated financial results for the quarter and financial year ended 31.03.2024. 2.Audited standalone and consolidated accounts of the Company together with Directors and Auditors reports. 3. Recommendation of Dividend if any for the financial year ended 31.03.2024. 4.Appoinment of Internal Auditors Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024. Board of Directors of the Company has met today and inter alia transacted the following business, 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM. 2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25. (As Per BSE Announcement Dated on: 28/05/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
